Introduction
Epilepsy is one of the most common neurological conditions, with more than 50 million people affected worldwide [1] . Studies in well-defined populations with newly diagnosed epilepsy have shown the majority of patients achieve remission at some time after the onset of the disease, and about one-third of patients have recurrent seizures despite optimal therapy with available antiepileptic drugs (AED) [2] [3] [4] . Four different patterns of clinical outcome have been identified: early remission, late remission, relapsingremitting course, and never remission [5, 6] . To formulate rational treatment plans, it is important to understand the different patterns of response to AED treatment and associated predictors.
Several factors was found to be negatively associated with early remission in patients with newly diagnosed epilepsy, such as early age at seizure onset, etiology, long duration of epilepsy, and electroencephalography (EEG) abnormality [7] [8] [9] . However, limited data were available on prognostic indicators of late remission, particularly in Chinese, necessitating studies on this field. Moreover, there were no studies carried out to assess the association between patients' compliance and late remission. Therefore, we are aiming to explore the patterns of treatment outcome and to identify factors predictive of late remission in a prospective cohort of Chinese patients with newly diagnosed epilepsy.
Materials and methods

Population
The prospective, observational study was performed at a tertiary hospital which served a population of approximately 350,0000 each year. Newly diagnosed patients were included from 2009 to September 2012 when a definite diagnosis of epilepsy was made according to the International League against Epilepsy (ILAE) [10] (i.e., two or more unprovoked seizures at least 24 h apart, or if they had a definite epileptic focus on brain MRI or epileptiform discharges on EEG if they had suffered only one epileptic seizure Purpose: Limited data have focused on predictive factors of late remission in patients with newly diagnosed epilepsy. We are aiming to identify prognostic predictors of late remission in a prospective cohort of Chinese patients. Methods: Patients with newly diagnosed epilepsy were included from 2009 to September 2012 at a tertiary hospital, with follow-up of at least two years. Early remission was defined by seizure free either immediately or within six months of treatment initiation, late remission was defined by seizure free achieved after more than six months. All analyses were performed with SPSS 13.0 software. Results: A total of 223 patients were included, and followed for an average of 43 months. 115 patients (51.6%) achieved early remission and 39 patients (17.5%) achieved late remission. Multivariable logistic regression analysis demonstrated more than 3 seizures prior to treatment (OR = 3.12, 95% CI 1.39-7.04, p = 0.006) and multiple seizure types (OR = 2.49, 95% CI 1.02-6.11, p = 0.046) may predict late remission. However, nonadherence was not significantly associated with late remission. Conclusion: Patients with a high frequency of seizures prior to treatment or multiple seizure types may achieve late remission. Particular consideration should be given to these patients.
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with confirmation by a neurologist). Patients were excluded if they (1) refused treatment with AEDs, (2) were taking more than one AED, (3) had received epilepsy surgery during the follow-up, (4) had severe hepatic or renal diseases. The study was approved by the Second Affiliated hospital of Zhejiang University School of Medicine Ethics Committee. For each eligible case, the following data were collected at the first visit: patient demographics, age at seizure onset, pretreatment duration, seizure frequency before starting AED, seizure types, past history (i.e., head trauma, tumor, stroke, encephalitis), family history of epilepsy, febrile seizures, EEG and MRI findings. Monotherapy was recommended when starting treatment, and all the drug choice and schedule were done by standard. Patients were evaluated at 4 weeks after treatment initiation and then at 6-month intervals thereafter. At each visit, seizure frequency, choice of AEDs, and response to AEDs were routinely recorded. Patients were followed up until the end of June 2015, i.e., for at least two years. Multiple seizure types were defined as two or more seizure types, which included simple partial seizure, complex partial seizure, tonic-clonic seizures, etc. Adherence was examined by the validated Chinese version of the MMAS-4 (4-item Morisky Medication Adherence Scale) [11] . Adherence was defined as a ''no'' answer to every question, and nonadherence was defined as a ''yes'' answer to one or more questions.
Definition
Patterns of seizure outcome over time were classified according to pre-selected definition. The timing point was set in accordance to Brodie's study [6] . Remission was considered as a period of uninterrupted seizure free lasting one year or longer at any time and categorized into early and late remissions. Early remission was achieved either immediately or within six months of treatment initiation, as opposed to late remission, which was achieved after more than six months of treatment. Relapsing-remitting course described the occurrence of repeated seizures after remission achieved. Never remission was defined as never enter one-year remission during the follow-up. Sustained remission was defined as seizure free until the end of follow-up. According to the definition proposed by the ILAE, drug resistant epilepsy (DRE) was defined as the failure of two well-tolerated and appropriately chosen AEDs, whether as monotherapies or in combination, to achieve sustained seizure free for either one year or for a period equal to three times of the pre-intervention inter-seizure time, whichever was longer.
Data analyses
The continuous data were described as mean (range). Among those patients who achieved early and late remission, each predictive factor was tested with two-tailed chi-square or Fisher's exact tests. Factors with significantly different distribution were further assessed by multivariate logistic regression model. The odds ratio (OR) and 95% confidence interval (CI) were calculated. The p value of < 0.05 was considered as statistically significant. Additionally, a time-dependent analysis on cumulative remission was calculated with the Kaplan-Meier method. All analyses were performed with SPSS 13.0 software.
Results
Study characteristic
A total of 250 patients were diagnosed with epilepsy and none had previously received AEDs. 27 patients (10.8%) were excluded from analysis because of lack of follow-up information. Finally, outcomes were known for the remaining 223 patients. The median (range) age at referral was 28 (8-88) years, the median (range) age at the onset of epilepsy was 23 (2-85) years, and the median (range) duration of the follow-up was 43 (26-80) months. The general characteristics of the sample was shown in Table 1 .
Seizure outcome
As shown in Fig. 1 , of 223 patients with newly diagnosed epilepsy, 154 patients (69.1%) entered one year or longer seizure free: 115 patients (51.6%) achieved early remission and 39 patients (17.5%) achieved late remission. Of these, 96 (43.0%) and 32 patients (14.3%), respectively, were in sustained remission at the last follow-up. The remaining 26 (11.7%) patients relapsed, indicating a remitting-relapsing course of epilepsy. Besides, 69 (30.9%) patients never experienced a one-year remission during the AED therapy. Among them, 44 (19.7%) patients failed to achieve remission after using at least two AEDs and were thus defined as having DRE. The cumulative time-dependent probability of remission was performed using Kaplan-Meier method, which was seen in Fig. 2 . The median period of time needed to achieve remission was 24.8 months (range 0-74 months). 
Factors predictive of late remission
As shown in Table 2 , the result demonstrated a high frequency of pretreatment seizures and multiple seizure types were predictive factors influencing the timing point of seizure remission in patients with newly diagnosed epilepsy (P < 0.05). However, there were no significant difference in gender distribution, occupation, residence, education, age at onset, febrile seizure, past history, family history, seizure type, pretreatment duration, epileptiform discharges on EEG, MRI findings or adherence between early remission and late remission group. In the multivariable logistic regression model, prognostic predictors associated with late remission were identified: more than 3 seizures prior to treatment (OR = 3.12, 95% CI 1.39-7.04, p = 0.006) and multiple seizure types (OR = 2.49, 95% CI 1.02-6.11, p = 0.046) ( Table 3 ).
Discussion
By utilizing a prospective cohort of Chinese patients with newly diagnosed epilepsy, our study demonstrated the response to AEDs could be a dynamic process. Early remission was achieved in 51.6% newly diagnosed patients, and late remission was subsequently achieved in 17.5% patients. Of these, 43.0% and 14.3% patients, respectively, remained remission during the follow-up, and the remaining 11.7% relapsed. Furthermore, a high frequency of pretreatment seizures and multiple seizure types were revealed to be the factors predictive of late remission, however nonadherence may not be associated with late remission.
The proportion of patients achieving remission varied through studies, depending on population and definitions of remission. Our result was in keeping with Brodie's study [6] , which included a total of 1,098 patients, indicating 47.7% patients became seizure free within 6 months, 27.5% had seizure free after 6 months, and the remaining 24.8% patients had never seizure free after treatment. In a retrospective study of 356 newly diagnosed patients by Del Felice [12] , 32.7% achieved early remission and 10.8% achieved late remission. The remission rated lower than ours, which could be due to the stringent definition of early and late remission, as early remission was defined as a 2-year seizure control immediately after initial AED treatment, while late remission was defined as a 2-year seizure control achieved at least 24 months after treatment start. Moreover, an Italian study performed by Gasparini indicated only 23% patients with newly diagnosed cryptogenic focal epilepsy attained seizure remission during follow-up, as the remission was defined as the absence of any seizure for at least five years [13] . In a Chinese cohort of 180 patients [14] , Zhang et al. found early remission was reached in 69.4% newly diagnosed patients, and 10.6% entered late remission whereas 20% patients failed to achieve remission. The higher remission rate could also be explained by the different definition, because in their study early remission was defined as one-year seizure free within the first year of treatment initiation, as opposed to late remission, which was defined after more than first year of treatment.
Compared to early remission, it was reasonable that late remission may bring patients more seizures, resulting in anxiety, depression and poor quality of life [15] [16] [17] . Therefore, identification of the pattern of remission may be useful to develop alternative interventions to prevent late remission. Our result indicated patients with more than 3 seizures before treatment or multiple seizure types exhibited a higher possibility of late remission. In Del Felice A's study [12] , pretreatment seizure number was classified into 1, 2-5 and 6+, suggesting the OR of late remission was 2.7 (1.0-6.8) in patients with 2-5 partial seizures and 6.7 (2.3-19. 3) in patients with more than five partial seizures, which was in accordance with our result. As for multiple seizure types, previous studies have consistently indicated it may be predictive of a poor initial response and long-term outcome [18, 19] . However, It was still poorly understood why multiple seizure types and a high number of pretreatment seizures were associated with late remission. One of the possible mechanisms could be intrinsic disease severity. It could be determined by a predetermined, complex interaction between underlying pathology, individual genetics and the environment, reflecting the pattern of treatment outcome [20, 21] . Studies have suggested one of biomarkers for intrinsic disease severity was a high number of seizures during the early phase of epilepsy [22] , thus it was reasonable that pretreatment seizure number and multiple seizure types may predict late remission in newly diagnosed epilepsy. In addition, repeated seizures have been shown to produce neuronal loss and mossy fiber sprouting in the hippocampus, which in turn can reinforce their production forming excitatory recurrent circuits, and increase the severity of induced seizures [23, 24] . It was called seizure beget seizures [25] . According to this phenomenon, a high number of pretreatment seizures may also be responsible for delayed remission.
Adherence was not found to influence the timing point of remission in our population, whereas past evidences have reported poor adherence to AEDs may affect seizure control, decrease quality of life and productivity, and even increase morbidity and mortality [26] [27] [28] . To the best of our knowledge, it was the first to investigate the association between nonadherence and late remission. Perhaps not surprisingly, this finding supported the above theory that late remission was explained at least in part by intrinsic characteristics of epilepsy. Interestingly, we even found the possibility of nonadherence was ever higher in patients with early remission, compared to those with late remission (52.2% versus 43.6%). It may be explained by patients' subjective decision, as patients with seizure control may often let down their guard or be neglect of treatment. However, the association between nonadherence and late remission needs further confirmation.
The study has some limitations. First, the timing point between early remission and late remission was not consistent between each study, patients who entered remission between 6 months to 2 years would be classified into different groups from different studies, which may exert unknown effects in our study. Second, our study was undertook at a local tertiary center, thus the result may not be representative for all regions of China. Third, because the patterns of clinical outcome in newly diagnosed epilepsy was dynamic, early intractability may become remission over time, which would enlarge the sample of late remission group. Thus, large sample studies with a longer follow-up are needed to validate our finding.
Conclusion
In conclusion, we have demonstrated that more than 3 seizures before treatment and multiple seizure types may be prognostic factors predictive of late remission in patients with newly diagnosed epilepsy. Thus, particular consideration should be given to the patients with a high frequency of seizures prior to treatment and multiple seizure types when prescribing AEDs.
